News Snapshot:
Rouen-based Robocath (70 employees), which designs, develops and markets robotic assistive solutions for the treatment of cardiovascular disease, completed a Cathbot joint venture with the first clinical trial in China this summer. 149 patients were treated in six months at four Chinese centers. This is the first step in obtaining marketing approval for R-One™, Robocath’s robotic coronary angioplasty solution, from the National Medical Products Administration (NMPA). This clinical trial of vascular robotics is the first of its kind in China. The R-One market launch in China is announced for 2023. More than a million angioplasties are performed annually in China...
